{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:27:33Z","timestamp":1771655253458,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Celgene Corporation, USA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.leukres.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T17:55:55Z","timestamp":1551376555000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9623-6645","authenticated-orcid":false,"given":"Jen-Chin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Kundra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenath","family":"Kodali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gotlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gardith","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Tribie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"October","key":"10.1016\/j.leukres.2019.02.010_bib0005","article-title":"Checkpoint blocking antibodies in cancer immunotherapy","author":"Kyi","year":"2013","journal-title":"FEBS Lett."},{"issue":"March (4)","key":"10.1016\/j.leukres.2019.02.010_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2019.02.010_bib0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.02.010_bib0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7 family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.02.010_bib0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"issue":"October (7)","key":"10.1016\/j.leukres.2019.02.010_bib0030","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2019.02.010_bib0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"September (19)","key":"10.1016\/j.leukres.2019.02.010_bib0040","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"793","key":"10.1016\/j.leukres.2019.02.010_bib0045","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2019.02.010_bib0050","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.02.010_bib0055","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2019.02.010_bib0060","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"Kwon ED (2007) PD-1 is expressed by tumor infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2019.02.010_bib0065","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2019.02.010_bib0070","series-title":"Fda Approves Keytruda for Ad- Vanced Melanoma","author":"Adminstration USFaD","year":"2014"},{"key":"10.1016\/j.leukres.2019.02.010_bib0075","series-title":"Fda Approves Keytruda for Ad- Vanced Non-Small Cell Lung Cancer","author":"Administration USFaD","year":"2015"},{"key":"10.1016\/j.leukres.2019.02.010_bib0080","series-title":"Fda Approves Opdivo for Advanced Melanoma","author":"Administration USFaD","year":"2014"},{"key":"10.1016\/j.leukres.2019.02.010_bib0085","series-title":"Fda Expands Approved use 0f Opdivo to Treat Lung Cancer","author":"Administration USFaD","year":"2015"},{"key":"10.1016\/j.leukres.2019.02.010_bib0090","series-title":"Nivolumab (Opdivo) for Hodgkin Lymphoma","author":"Administration USFaD","year":"2015"},{"key":"10.1016\/j.leukres.2019.02.010_bib0095","series-title":"Fda Approves Opdivo to Treat Ad- Vanced Form of Kidney Cancer","author":"Administration USFaD","year":"2015"},{"key":"10.1016\/j.leukres.2019.02.010_bib0100","series-title":"Fda Approves Keytruda (Pembrolizumab) for Head and Neck Cancer","author":"Administration USFaD","year":"2016"},{"issue":"21","key":"10.1016\/j.leukres.2019.02.010_bib0105","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood.V122.21.2837.2837","article-title":"Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) expression and myeloid derived suppressor cells (MDSC) in myeloid neoplasms implicate the mechanism of IMiD treatment of myelofibrosis","volume":"122","author":"Kundra","year":"2013","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.leukres.2019.02.010_bib0110","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.02.010_bib0115","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","article-title":"Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia","volume":"11","author":"Tamura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2019.02.010_bib0120","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.leukres.2019.02.010_bib0125","article-title":"Programmed death ligand (PD-L1) expression is increased in spleens of myelo- fibrosis patients","author":"Craig","year":"2016","journal-title":"United States and Canadian Academy of 2016 Annual Meeting"},{"issue":"February (429)","key":"10.1016\/j.leukres.2019.02.010_bib0130","article-title":"Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"November (19)","key":"10.1016\/j.leukres.2019.02.010_bib0135","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.02.010_bib0140","unstructured":"PD-1 Inhibition in Advanced Myeloproliferative Neoplasms \u2013 (PI, John Mascarenhas, MD), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03065400."},{"issue":"3","key":"10.1016\/j.leukres.2019.02.010_bib0145","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regu- latory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregula- tion of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.leukres.2019.02.010_bib0150","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"March (6)","key":"10.1016\/j.leukres.2019.02.010_bib0155","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.leukres.2019.02.010_bib0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PDL1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2019.02.010_bib0165","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferongamma and can be reversed using MEK \u2009inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"February (3)","key":"10.1016\/j.leukres.2019.02.010_bib0170","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."},{"issue":"July (1)","key":"10.1016\/j.leukres.2019.02.010_bib0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"December (52)","key":"10.1016\/j.leukres.2019.02.010_bib0180","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of mmunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.leukres.2019.02.010_bib0185","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regu- lates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J. Immunol."},{"issue":"May (7)","key":"10.1016\/j.leukres.2019.02.010_bib0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection","volume":"12","author":"Kao","year":"2011","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.leukres.2019.02.010_bib0195","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1084\/jem.20130208","article-title":"Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection","volume":"211","author":"Lu","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2019.02.010_bib0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.02.010_bib0205","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood.V128.22.1945.1945","article-title":"Derangements of Toll-like receptors, inflammatory cytokines, and reactive oxygen species in Philadelphia chromosome-negative myeloproliferative neoplasm: implicate roles of inflammation in the pathogenesis","volume":"128","author":"Shi","year":"2016","journal-title":"Blood"},{"issue":"January (2)","key":"10.1016\/j.leukres.2019.02.010_bib0210","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.18632\/oncotarget.6662","article-title":"Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression","volume":"7","author":"Pinton","year":"2016","journal-title":"Oncotarget."},{"issue":"12","key":"10.1016\/j.leukres.2019.02.010_bib0215","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferongamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"February (3)","key":"10.1016\/j.leukres.2019.02.010_bib0220","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T22:40:00Z","timestamp":1606603200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":44,"alternative-id":["S0145212619300360"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.02.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}